Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: A safety, feasibility, and efficacy study from the Hoosier oncology group

Journal of Thoracic Oncology

Volumn 5, Issue 12, 2010, Pages 2008-2011

  Jalal, Shadia ^a   Bedano, Pablo ^b   Einhorn, Lawrence ^a   Bhatia, Sumeet ^c   Ansari, Rafat ^d   Bechar, Naftali ^d,e   Koneru, Karuna ^f   Govindan, Ramaswamy ^g,h   Wu, Jingwei ⁱ   Yu, Menggang ⁱ   Schneider, Bryan ^a   Hanna, Nasser ^a  

^a INDIANA UNIVERSITY   (United States)

^b Section of Hematology Oncology   (United States)

^c Community Regional Cancer Center ^*  (United States)

^d Northern Indiana Cancer Research Consortium   (United States)

^e Community Oncology Center ^*  (United States)

^f Cancer Care Center of Southern Indiana   (United States)

^g USA   (United States)

^h INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ NONE

Author keywords

Bevacizumab; Paclitaxel; Relapsed small cell

Indexed keywords

BEVACIZUMAB; PACLITAXEL; TOPOTECAN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 1154; VASCULOTROPIN 1498; VASCULOTROPIN 2578; VASCULOTROPIN 634; VASCULOTROPIN 936;

ADULT; AGE DISTRIBUTION; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LUNG HEMORRHAGE; LUNG SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; SEX RATIO; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

EID: 78650483125     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181f77b6e     Document Type: Article

References (15)

1. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24:4539-4544. (Pubitemid 46630948)
2. Ettinger DS, Finkelstein DM, Sarma RP, et al. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 1995;13: 1430-1435.
3. Kirschling RJ, Grill JP, Marks RS, et al. Paclitaxel and G-CSF in previously untreated patients with extensive stage small-cell lung cancer: a phase II study of the North Central Cancer Treatment Group. Am J Clin Oncol 1999;22:517-522.
4. Smit EF, Fokkema E, Biesma B, et al. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer 1998;77:347-351. (Pubitemid 28029555)
5. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 2006;355: 2542-2550. (Pubitemid 44917502)
6. Lucci M, Mussi A, Fontanini G, et al. Small cell lung carcinoma (SCLC): the angiogenic phenomenon. Eur J Cardiothorac Surg 2002; 21:1105-1110. (Pubitemid 34615629)
7. Dowell JE, Amirkhan RH, Lai WS, et al. Survival in small cell lung cancer is independent of tumor expression of VEGF and COX-2. Anticancer Res 2004;24:2367-2373.
8. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357: 2666-2676.
9. Schneider BP, Radovich M, Sledge GW, et al. Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Res Treat 2008;111:157-163. (Pubitemid 352009224)
10. Waterhouse DM, Morgan SK, Spigel DR, et al. Phase II study of oral topotecan plus bevacizumab (topo-bev) for second line treatment of small cell lung cancer (SCLC). J Clin Oncol 2010:Abstract 7055.
11. Horn L, Dahlberg SE, Sandler AB, et al. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol 2009;27:6008-6011.
12. Ready N, Dudeck AZ, Wan XF, et al. CALGB30306:A phase II study of cisplatin (C),irinotecan (I) and bevacizumab (B) for untreated extensive stage small cell lung cancer (ES-SCLC). J Clin Oncol 2007;25:Abstract 7564.
13. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small cell lung cancer. N Engl J Med 2002;346:85-91. (Pubitemid 34438898)
14. Spigel DR, Greco A, Zubkus JD, et al. Phase II trial of irinotecan,carboplatin, and bevacizumab in the treatment of patients with extensivestage, small cell lung cancer. J Thorac Oncol 2009;4:1555-1560.
15. Schneider BP, Wang M, Radovich M, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008;26:4672-4678.